Annexin derivatives with endogenous chelation sites

Details Annexin derivatives with endogenous chelation sites Annexin derivatives with endogenous chelation sites

2007-04-17

2007-04-17

Huff, Sheela J. (Department: 1643)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C530S324000, C514S012200

Reexamination Certificate

active

11012708

ABSTRACT:
Modified annexins having an N-terminal chelation site comprising an amino acid extension are disclosed. The amino acid extension includes an amino acid sequence X1-Gly-X2, where X1and X2are selected from Gly and Cys, where at least one of X1or X2is Cys. Radionuclides are readily chelated by the modified annexins to provide radiolabeled annexins useful in imaging vascular thrombi and apoptosis in vivo.

REFERENCES:
patent: 5591633 (1997-01-01), Saino et al.
patent: 5849261 (1998-12-01), Dean et al.
patent: 5968477 (1999-10-01), Kasina et al.
patent: 0 339 285 (1989-11-01), None
patent: WO 95/19791 (1995-07-01), None
patent: WO 95/34315 (1995-12-01), None
patent: WO 96/17618 (1996-06-01), None
patent: WO 98/04294 (1998-02-01), None
Blankenberg, F.G., et al., “Imaging of Apoptosis (Programmed Cell Death) with99mTc Annexin V,”The Journal of Nuclear Medicine 40(1):184-191, Jan. 1999.
Blankenberg, F.G., et al., “In VivoDetection and Imaging of Phosphatidylserine Expression During Programmed Cell Death,”Proceedings of the National Academy of Sciences. 95:6349-6354, May 1998.
George, A.J.T., et al., “Radiometal Labeling of Recombinant Proteins by a Genetically Engineered Minimal Chelation Site: Technetium-99m Coordination by Single-Chain Fv Antibody Fusion Proteins Through a C-Terminal Cysteinyl Peptide,”Proceedings of the National Academy of Sciences. 92:8358-8362, Aug. 1995.
Giblin, M.F., et al., “Synthesis and Characterization of Rhenium-Complexed α-Melanotropin Analogs,”Bioconjugate Chem. 8(3):347-353, 1997.
Huston, J.S., et al., “Single-Chain Fv Radioimmunotargeting,”The Quarterly Journal of Nuclear Medicine 40(3):320-333, Sep. 1996.
Liberatore, M., et al., “Efficient One-Step Direct Labelling of Recombinant Antibodies with Technetium-99m,”European Journal of Nuclear Medicine 22(11):1326-1329, Nov. 1995.
Stalteri, M.A., et al., “Comparison of the Stability of Technetium-Labeled Peptides to Challenge with Cysteine,”Bioconjugate Chem. 10(1):130-136, 1999.
Stratton, J.R., et al., “Selective Uptake of Radiolabeled Annexin V on Acute Porcine Left Atrial Thrombi,”Circulation 92(10):3113-3121, Nov. 15, 1995.
Vriens, P.W., et al., “The Use of Technetium TC99M Annexin V for In Vivo Imaging of Apoptosis During Cardiac Allograft Rejection,”The Journal of Thoracic and Cardiovascular Surgery 116(5):844-853, Nov. 1998.

Affiliated with

Also associated with

Rating

Annexin derivatives with endogenous chelation sites does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Annexin derivatives with endogenous chelation sites, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Annexin derivatives with endogenous chelation sites will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3780021